​The world's first bispecific antibody drug simultaneously targeting CD47 and CD20 has been approved clinical trial by NMPA

ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. announced that the bispecific antibody drug (project number: IMM0306) independently developed and simultaneously targeting CD47 and CD20 has recently obtained the clinical trial license of NMPA (Acceptance......

2020-07-09

The second general meeting of shareholders of ImmuneOnco was successfully held

The founder and chairman of ImmuneOnco, Dr. Tian Wenzhi, delivered a speech on the spot. He reviewed the company's development history and the achievements achieved in stages, summarized the work of the company in 2019, and introduced the new dr...

2020-06-14

The IMM01 project patent of ImmuneOnco was authorized by the patent offices of the United States and Japan

...

2020-05-28

Recruitment of clinical trials of IMM0306 in the treatment of refractory or recurrent CD20 positive B-cell non Hodgkin's lymphoma

IMM0306 is a recombinant human SIRPα and anti-CD20 antibody fusion protein, which is independently developed by ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. IMM0306 can bind to CD20 on tumor cell membrane and kill tumor cells through ADCP, ADCC and CDC; ......

2020-05-14

The Phase I clinical trial launching meeting of IMM0306 project was held

...

2020-04-17